YCANTH (Cantharidin)
Molluscum Contagiosum
ApprovedCommercial Launch (Japan, Feb 2026)
Key Facts
Indication
Molluscum Contagiosum
Phase
Approved
Status
Commercial Launch (Japan, Feb 2026)
Company
About Torii Pharmaceutical
Japanese dermatology-focused pharmaceutical company specializing in rare skin disease treatments through small molecule and topical formulations.
View full company profileTherapeutic Areas
Other Molluscum Contagiosum Drugs
| Drug | Company | Phase |
|---|---|---|
| Zabalafin Hydrogel (AB-101a) | Alphyn Biologics | Phase 2 |
| Exploratory Asset | Veradermics | Discovery |
| ZELSUVMI™ (berdazimer topical gel, 10.3%) | Pelthos Therapeutics | Approved |
| YCANTH (VP-102) | Verrica Pharmaceuticals | Approved |